Gå til innhold
English A A A

Bjørn Blomberg

førsteamanuensis II

Klinisk institutt 2

Hjemmeside: http://www.uib.no/personer/Bjorn.Blomberg

Stilling: førsteamanuensis II

Telefon: 55 97 29 60


Besøksadresse: Haukeland universitetssykehus, Laboratoriebygget

Antibiotikaresistens, sepsis, malaria, tuberkulose


Publikasjoner i Cristin



1. Aase Berg, Sam Patel, Nina Langeland, and Bjorn Blomberg. Falciparum malaria and HIV-1 in hospitalized adults in Maputo, Mozambique: does HIV-infection obscure the malaria diagnosis?  Malar J. 2008; 7: 252. 


2. Tellevik MG, Sollid JE, Blomberg B, Jureen R, Urassa WK, Langeland N: Extended-spectrum beta-lactamase (ESBL) type SHV-12 producing Enterobacteriaceae causing septicemia in Tanzanian children: epidemiology and vectors for horizontal transfer of antimicrobial resistance. Diagn Microbiol Infect Dis 2007;59(3):351-4


3. Blomberg B, Manji KP, Urassa WK, Tamim BS, Mwakagile DSM, Jureen R, Msangi V, Tellevik MG, Holberg-Petersen M, Harthug S, Maselle SY, Langeland N. Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infectious Diseases 2007;7:43.



4. Blomberg B, Olsen BE, Hinderaker SG, Langeland N, Gasheka P, Jureen R, Kvåle G, Midtvedt T. Antimicrobial resistance in urinary bacterial isolates from pregnant women in rural Tanzania: implications for public health. Scand J Infect Dis 2005;37(4):262-268. 



5. Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DSM, Urassa WK, Fataki M, Msangi V, Tellevik MG, Maselle SY, Langeland N. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 2005;43(2):745-749.



6. Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscigno G, Wire R, Laing R, Evans P, Moore T. Fixed dose combinations for tuberculosis: Lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol. 2004 Nov;26(9):703-21.


7. Blomberg B, Mwakagile DSM, Urassa WK, Maselle SY, Mashurano M, Digranes A, Harthug S, Langeland N. Surveillance of antimicrobial resistance at a tertiary hospital in Tanzania. BMC Public Health 2004;4:45. http://www.biomedcentral.com/1471-2458/4/45


8. Vaagland H, Blomberg B, Krüger C, Naman N, Jureen R, Langeland N. Nosocomial outbreak of neonatal Salmonella enterica serotype Enteritidis meningitis in a rural hospital in northern Tanzania. BMC Infectious Diseases 2004;4:35. http://www.biomedcentral.com/1471-2334/4/35


9. Blomberg B, Fourie PB. Fixed-dose combination drugs for tuberculosis: application in standardized treatment regimens. Drugs 2003;63(6):535-553. 


10. Blomberg B. [Filler] A memorable patient: An aunt without health insurance. BMJ 2003; 326: 279. http://bmj.com/cgi/content/full/326/7383/279


11. Strand TA, Hollingshead SK, Julshamn K, Briles DE, Blomberg B, Sommerfelt H. Effects of zinc deficiency and pneumococcal surface protein A immunization on zinc status and the risk of severe infection in mice. Infection and immunity; 2003;71(4):2009-2013. http://iai.asm.org/cgi/content/full/71/4/2009


12. Blomberg B, Evans P, Phanouvong S, Nunn P. [WHO Report] Informal consultation on 4-drug fixed-dose combinations compliant with the WHO Model List of Essential Drugs. Geneva, Switzerland, 15-17 August 2001. Geneva: UNPD, World Bank, WHO Special Programme for Research & Training in Tropical Diseases (TDR); 2002. Report No.: TDR/TB/02.1, WHO/CDS/TB/2002.299. 



13. Blomberg B, Rieder HL, Enarson DA. [Editorial] Kristian Andvord's impact on the understanding of tuberculosis epidemiology. Int J Tuberc Lung Dis 2002;6(7):557-9. 


14. Andvord KF, Wijsmuller G, Blomberg B. [Translation] What can we learn by following the development of tuberculosis from one generation to another? 1930 [classical article]. Int J Tuberc Lung Dis 2002;6(7):562-8. 


15. Blomberg B, Spinaci S, Fourie PB, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Org 2001;79:61-8. http://www.who.int/docstore/bulletin/tableofcontents/2001/vol.79no.1.html


16. Blomberg B, Maher D, Spinaci S. [Book chapter] Rational use of drugs in the treatment of tuberculosis. In: Chaudhury RR, editor. International experience in rational use of drugs. Bangkok: College of Public Health, Chulalongkorn University, Bangkok/UNESCO Chair in rational use of drugs; 2000. p. 128-165. 


17. Sbarbaro J, Blomberg B, Chaulet P. [Editorial] Fixed-dose combination formulations for tuberculosis treatment. Int J Tuberc Lung Dis 1999;3(11 Suppl 3):S286-8. 


18. Blomberg B, Kitler ME, Milstien J, Dellepiane N, Fanning A, Norval PY, et al. Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model? Int J Tuberc Lung Dis 1999;3(11 Suppl 3):S371-80; discussion S81-7. 


19. Norval PY, Blomberg B, Kitler ME, Dye C, Spinaci S. Estimate of the global market for rifampicin-containing fixed-dose combination tablets. Int J Tuberc Lung Dis 1999;3(11 Suppl 3):S292-300; discussion S17- 21. 


20. Laing R, Fourie B, Ellard G, Sesay M, Spinaci S, Blomberg B, et al. [WHO Report] Fixed dose combination tablets for the treatment of tuberculosis. Report from an informal meeting held in Geneva, Tuesday, 27 April 1999. Geneva: World Health Organization; 1999. Report No.: WHO/CDS/CPC/TB/99.267. http://www.who.int/gtb/publications/fdc/index.htm

21. Blomberg B. Management of side effects of antituberculosis drugs (Book Chapter). In "Tuberculosis - A comprehensive clinical reference. Edited by Schaaf, HS, Zumla A.


HIV, tuberkulose, tropemedisin, Universitetet i Bergen. Indremedisin, infeksjonssykdommer for medisinstudenter. Tropemedisin, CMC, Vellore, India.

Førsteamanuensis, Inst. for indremedisin, overlege i infeksjonssykdommer, Medisinsk Avdeling, Haukeland